Identification of novel topoisomerase II alpha inhibitors by virtual screening, molecular docking, and bioassay
- PMID: 34310071
- DOI: 10.1111/cbdd.13927
Identification of novel topoisomerase II alpha inhibitors by virtual screening, molecular docking, and bioassay
Abstract
Breast cancer is one of the most common tumors, and its treatment still leaves room for improvement. Topoisomerase II alpha is a potential target for the treatment of human diseases such as breast cancer. In this article, we attempted to discover a novel anticancer drug. We have used the topoisomerase II alpha protein-Homo sapiens (Human) to hierarchically screen the Maybridge database. Based on their docking score, the top hit compounds have been assayed for inhibition in a topoisomerase II pBR322 DNA relaxation assay in vitro. Candidate compound 6 (CP6) was found to have the best inhibitory effect for topoisomerase II among the 20 tested compounds. In addition, CP6 had potent cytotoxicity against eight tested tumor cell lines. At the same time, CP6 was shown to have potential anti-multidrug resistance capabilities. This study identifies CP6, which can contribute to the development of new topoisomerase II inhibitors as anticancer agents.
Keywords: Maybridge database; anticancer drug; molecular docking; topoisomerase II alpha; virtual screening.
© 2021 John Wiley & Sons Ltd.
Similar articles
-
Novel nalidixic acid derivatives targeting topoisomerase II enzyme; Design, synthesis, anticancer activity and effect on cell cycle profile.Bioorg Chem. 2019 Mar;83:262-276. doi: 10.1016/j.bioorg.2018.10.058. Epub 2018 Oct 30. Bioorg Chem. 2019. PMID: 30391699
-
Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.PLoS One. 2014 Dec 9;9(12):e114904. doi: 10.1371/journal.pone.0114904. eCollection 2014. PLoS One. 2014. PMID: 25489853 Free PMC article.
-
Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.Bioorg Chem. 2020 Dec;105:104399. doi: 10.1016/j.bioorg.2020.104399. Epub 2020 Oct 21. Bioorg Chem. 2020. PMID: 33113414
-
Bioassays and In Silico Methods in the Identification of Human DNA Topoisomerase IIα Inhibitors.Curr Med Chem. 2018;25(28):3286-3318. doi: 10.2174/0929867325666180306165725. Curr Med Chem. 2018. PMID: 29508675 Review.
-
Topoisomerases as anticancer targets.Biochem J. 2018 Jan 23;475(2):373-398. doi: 10.1042/BCJ20160583. Biochem J. 2018. PMID: 29363591 Free PMC article. Review.
Cited by
-
Exploring Carboxamide Derivatives as Promising Anticancer Agents: Design, In Vitro Evaluation, and Mechanistic Insights.Int J Mol Sci. 2025 Jun 19;26(12):5903. doi: 10.3390/ijms26125903. Int J Mol Sci. 2025. PMID: 40565364 Free PMC article.
References
REFERENCES
-
- Ai, H., Zhang, L., Chang, A. K., Wei, H., Che, Y., & Liu, H. (2014). Virtual screening of potential inhibitors from TCM for the CPSF30 binding site on the NSIA protein of influenza A virus. Journal of Molecular Modeling, 20, 2142-2147.
-
- Ambure, P., Kar, S., & Roy, K. (2014). Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer’s agents. BioSystems, 116, 10-20. https://doi.org/10.1016/j.biosystems.2013.12.002
-
- Azarova, A. M., Lyu, Y. L., Lin, C. P., Tsai, Y. C., Wang, J. C., & Liu, L. F. (2007). Roles of DNA topoisomerase Ⅱ Isozymes in chemotherapy and secondary malignancies. Proceedings of the National Academy of Sciences of the United States of America, 104, 11014-11019.
-
- Bailly, C. (2012). Contemporary challenges in the design of topoisomerase Ⅱ inhibitors for cancer chemotherapy. Chemical Reviews, 112, 3611-3640.
-
- Barrett, J. F., Sutcliffe, J. A., & Gootz, T. D. (1990). In vitro assays used to measure the activity of topoisomerase. Antimicrobial Agents and Chemotherapy, 34, 1-7.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
